Cat. No. | Product name | CAS No. |
DC10300 |
Tbid
tBID is a selective inhibitor of homeodomain–interacting protein kinase 2 (HIPK2) with an IC50 of 0.33 µM. |
1639895-85-4 |
DC9586 |
Telatinib
Featured
Telatinib(Bay 57-9352) is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. |
332012-40-5 |
DC10044 |
ONO4059 analog
Featured
The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range. |
1351635-67-0 |
DC7065 |
Tivantinib (ARQ 197)
Featured
Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. |
905854-02-6 |
DC5078 |
Tivozanib(AV-951)
Featured
Tivozanib (AV-951, KRN-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 0.21 nM/0.16 nM/0.24 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met EGFR and IGF-1R. |
475108-18-0 |
DC7329 |
Toceranib(SU 11654; PHA 291639)
Featured
Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. |
356068-94-5 |
DC8494 |
Toceranib phosphate(SU 11654)
Featured
Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. |
874819-74-6 |
DC8223 |
TP-0903
Featured
TP-0903 is a a high-affinity Axl inhibitor with IC50 of 27 nM. |
1341200-45-0 |
DC8557 |
AG879
Featured
Tyrphostin AG 879 is a protein tyrosine kinase inhibitor with potent effects on TrkA. |
148741-30-4 |
DC10835 |
UM164
Featured
UM-164 is a Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer. |
903564-48-7 |
DC9289 |
UNC-2025 HCl
Featured
UNC-2025 is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3. |
2070015-17-5 |
DC7931 |
UNC2025
Featured
UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3. |
1429881-91-3 |
DC10127 |
UNC569
Featured
UNC569 is a novel small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. |
1350547-65-7 |
DC11073 |
UniPR1331
UniPR1331 (UniPR-1331) is a selective, orally available antagonist of Eph/ephrin interaction with pIC50 of 5.45, IC50 of 2.9 uM. |
1809170-59-9 |
DC3134 |
Vandetanib (ZD6474)
Featured
Vandetanib (Zactima, ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM. |
443913-73-3 |
DC7607 |
Vatalanib
Featured
Vatalanib (PTK787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. Phase 1/2. |
212141-51-0 |
DC8655 |
Vatalanib free base
Vatalanib free base (PTK787 free base) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. |
212141-54-3 |
DC11268 |
VEGFR2 kinase inhibitor I(SU-5408)
Featured
VEGFR2 kinase inhibitor I(SU-5408)is a potent, cell-permeable inhibitor of mouse VEGFR2 kinase (IC50 = 70 nM). |
15966-93-5 |
DC7657 |
WH-4-023
Featured
WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR. |
837422-57-8 |
DC7558 |
WP1130(Degrasyn)
Featured
WP1130(Degrasyn) is a novel selective small molecular deubiquitinase (USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and a Bcr/Abl destruction pathway activator with an IC50 of 1.8 μM for K562 cells. |
856243-80-6 |
DC10916 |
WY-135
WY-135 (WY135) is a novel potent inhibitor of ALK and ROS1 with IC50 of 1.2 and 0.48 nM, respectively. |
2163060-83-9 |
DC9775 |
WZ3146
Featured
WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I). |
1214265-56-1 |